Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 97,605 shares, a decrease of 35.1% from the September 30th total of 150,336 shares. Based on an average trading volume of 119,437 shares, the days-to-cover ratio is presently 0.8 days. Currently, 4.2% of the shares of the company are sold short.
Decoy Therapeutics Stock Performance
DCOY opened at $1.07 on Monday. The stock’s 50 day simple moving average is $2.16 and its 200-day simple moving average is $5.39. The stock has a market cap of $2.56 million, a PE ratio of -0.04 and a beta of 0.76. Decoy Therapeutics has a 1 year low of $0.90 and a 1 year high of $47.28.
Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($4.46) EPS for the quarter. The company had revenue of $0.23 million during the quarter. Equities analysts forecast that Decoy Therapeutics will post -8.96 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Decoy Therapeutics in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $30.00.
Read Our Latest Report on DCOY
Decoy Therapeutics Company Profile
Decoy Therapeutics is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms.
The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies.
Publicly available information about Decoy Therapeutics’ operating history, geographic presence and leadership is limited.
Read More
- Five stocks we like better than Decoy Therapeutics
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Decoy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decoy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
